NRx Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company, develops new treatments for the treatment of life-threatening central nervous system disorders and lung diseases. The company is headquartered in Wilmington, Delaware.
| Revenue (TTM) | $1.23M |
| Gross Profit (TTM) | 720,000 |
| EBITDA | $-16.12M |
| Operating Margin | -467.30% |
| Return on Equity | -683.00% |
| Return on Assets | -121.80% |
| Revenue/Share (TTM) | $0.06 |
| Book Value | $-0.50 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $24.24M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |